NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
AstraZeneca
I-Mab Biopharma US Limited
City of Hope Medical Center
Merck Sharp & Dohme LLC
Pfizer
Incyte Corporation
Masonic Cancer Center, University of Minnesota
Palleon Pharmaceuticals, Inc.
Incyte Corporation
Sichuan Enray Pharmaceutical Sciences Company
Institut Bergonié
Rutgers, The State University of New Jersey
Numab Therapeutics AG
Pfizer
NextCure, Inc.
Elevation Oncology
Stanford University
Deciphera Pharmaceuticals, LLC
Five Prime Therapeutics, Inc.
Sellas Life Sciences Group
Sandoz
Pfizer
NantCell, Inc.
Avera McKennan Hospital & University Health Center
ADC Therapeutics S.A.
University of Washington
Exelixis
Pfizer
CytomX Therapeutics
University Hospital, Ghent
Hoffmann-La Roche
pharmaand GmbH
Hoffmann-La Roche
AstraZeneca
OncoNano Medicine, Inc.
Herlev Hospital
Tesaro, Inc.
Tesaro, Inc.
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Duke University
NRG Oncology
Incyte Corporation
Incyte Corporation
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
National Institutes of Health Clinical Center (CC)
Pfizer